Veracyte touts results of Decipher classifier study

2019 09 17 23 20 9720 Prostate 400

Veracyte announced new data from a study touting the success of its Decipher Prostate Biopsy genomic classifier in helping guide treatment decisions for prostate cancer patients who are candidates for active surveillance. Their findings were published July 20 in Prostate Cancer and Prostatic Diseases.

Researchers reviewed the Decipher risk scores from 855 men in the study to evaluate the independent association of Decipher high scores with the time to conversion from active surveillance to radical therapy and the time to treatment failure.

Of the 241 evaluable patients who elected to undergo active surveillance, a high-risk Decipher score was independently associated with shorter radical therapy. Men with high-risk scores spent significantly less time on active surveillance than men with Decipher low/intermediate risk scores (13.6 months versus 33 months), the company said.

Similarly, among the 479 evaluable patients who underwent definitive treatment either initially or after a period of active surveillance, those with a Decipher high-risk score had a significantly shorter time to treatment failure as compared to those with lower scores.

Page 1 of 163
Next Page